Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

Abstract Number: 2046 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Efficacy In Acute Pain: Results From Two Phase 3 Studies
Roy D. Altman¹, Allan Gibofsky², Mark Jaros³ and Clarence Young⁴, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Summit Analytical, Denver, CO, ⁴Iroko Pharmaceuticals, Philadelphia, PA
Background/Purpose: Indomethacin is used to treat acute gouty arthritis and other acute pain conditions but, like other NSAIDs, is associated with dose-related gastrointestinal, cardiovascular, and…
Abstract Number: 2047 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Combined Safety From Two Phase 3 Studies In Patients With Acute Pain Following Elective Surgery
Allan Gibofsky¹, Roy D. Altman², Clarence Young³, Daniel Solorio⁴ and Jennifer Nezzer⁵, ¹Medicine and Public Health, Hospital for Special Surgery, New York, NY, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³Iroko Pharmaceuticals, Philadelphia, PA, ⁴Iroko Pharmaceuticals, LLC, Philadelphia, PA, ⁵Premier Research, Philadelphia, PA
Background/Purpose: Indomethacin is prescribed to treat acute pain and inflammation but, like other NSAIDs, is associated with dose-dependent gastrointestinal, cardiovascular, and renal adverse events (AEs).…
Abstract Number: 1095 • 2013 ACR/ARHP Annual Meeting
Pooled Safety Data From Randomized, Controlled Trials Of Diclofenac Sodium Topical Gel 1% In Subjects With Acute Pain
Roy D. Altman¹, Helmut Pabst², Hans-Georg Predel³, Bruno Giannetti⁴, Ian Burnett⁵, Morris Gold⁶ and Evan F. Ekman⁷, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Independent Physician, Gilching, Germany, ³German Sports University, Cologne, Germany, ⁴CRM clinical trials GmbH, Rheinbach, Germany, ⁵Novartis Consumer Health, Nyon, Switzerland, ⁶Novartis Consumer Health, Parsippany, NJ, ⁷Southern Orthopaedic Sports Medicine, Columbia, SC
Background/Purpose: Diclofenac sodium topical gel (DSG) 1% is clinically proven to be effective and well-tolerated for treatment of osteoarthritis pain and could be appropriate to…
Abstract Number: 415 • 2012 ACR/ARHP Annual Meeting
Hypoxia-Induced Endogenous Prostaglandin E2 Negatively Regulates Hypoxia-Enhanced Aberrant Overgrowth of Rheumatoid Synovial Tissue
Hirofumi Mitomi¹, Hidehiro Yamada¹, Toshiko Nozaki Shibata¹, Hiroshi Ito¹, Yoshioki Yamasaki², So Nomoto³, Atsushi Kusaba⁴, Hiroki Yamashita⁴ and Shoichi Ozaki¹, ¹Internal Medicine, St. Marianna University, Kawasaki, Japan, ²Medicine, St. Marianna University, Kawasaki, Japan, ³Department of Orthopedic Surgery and Rheumatology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan, ⁴Institute of Rheumatology, Ebina General Hospital, Ebina, Japan
Background/Purpose: During isometric exercise, the synovial joint tissue is prone to hypoxia, which is further enhanced in the presence of synovial inflammation. Hypoxia is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].